Dimension Inx designs and develops therapeutic products that restore tissue and organ function. The company uses biomaterials and a manufacturing process to create products with design versatility and a nuanced microarchitecture for biofunctionality.

Dimension Inx

Oxford Performance Materials, Inc. specializes in additive manufacturing technologies for medical devices and industrial hardware, providing solutions such as osteofab® medical devices and OXfab® industrial additive manufacturing.

Oxford Performance Materials, Inc.

Akkuratio offers additive manufacturing of industrial plastic components, including series production and rapid prototyping using 3D printing technologies.

Akkuratio

Dimension Inx is the architect of regenerative microenvironments. Our materials give the body a blueprint to heal itself. We take a materials-centric approach to solving patient needs. By creating structures that emulate the body’s microenvironment, we elicit an immediate regenerative response. 

We design for biofunctionality and manufacturability. Our platform is highly adaptable and not limited to any single material. Our collaborative studio approach allows us to co-create a lasting advantage by partnering with leading product and R&D organizations. Contact us to accelerate the development of new regenerative solutions today.

U.S. Department of Defense

Revolution’s Rise of the Rest Seed Fund

KdT Ventures

Better Ventures

Pathway Bioventures

Solas BioVentures

Alumni Ventures

Portal Innovations

Prime Movers Lab

Exciting news! Dimension Inx was named a finalist at Fast Company 2024 Innovation by Design Awards for our pioneering work developing CMFlex™!

CMFlex is a ready-to-use, flexible ceramic graft designed for bone reconstruction. It leverages a distinctive material microstructure and macroarchitecture for rapid vascularization and tissue integration to promote bone regeneration and remodeling, which can improve patient outcomes. To learn more about CMFlex, please visit https://www.cmflex3d.com/.

We’re proud and honored to be recognized alongside others solving the problems of today and tomorrow. Check out the full list of the best designs from small businesses: https://lnkd.in/g5HYNxRp. 

#FCDesignAwards #RegenerativeMedicine #CMFlex #ChicagoInnovation

Thanks for the shout-out, Desktop Health! We're grateful for the continued partnership.

We remain excited about this research program focused on using novel biomaterial scaffolds to drive follicular growth and maturation with our partners at Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University, especially our collaborator, Monica M. Laronda. 

#Bioprinting #RegenerativeMedicine #3DBioplotter #Biomaterials #ArtificialOvary #WomensHealth

We’re excited to share that we’ve launched a new website for CMFlex, the first FDA-cleared fully synthetic 3D-printed regenerative bone graft.

Our new website at www.cmflex3d.com provides detailed information about CMFlex's unique advantages, including its customizable fit, high porosity, and balanced flexibility and rigidity, designed for usability and to promote bone repair and regeneration.

We’re proud to be paving the way for a new generation of advanced biomaterials and encourage you to check out the new website!

#CMFlex #3dprinting #oralsurgery #dimensioninx #oralmaxillofacialsurgery #hydroxyapatite #bonegraft

We are excited to announce the recent issuance of Dimension Inx’s newest patent, US Patent No. 11,944,726, which covers the composition and manufacture of a novel, hydrogel-containing material family that is shelf-stable in its dry form, yet forms an interconnected gel network when hydrated, i.e., it’s “self-gelling”.
 
This material family is unique because it enables the creation of 3D-printable, gel-laden, nanostructured implants and #injectables that combine the biofunctional nano- and #microstructure characteristics of our biomaterials with the additional biological benefits of hydrogels. It also offers an innovative and simple approach to the delivery, localization, and stabilization of one or more hydrogels in vivo. It’s yet another demonstration of our platform’s unique capabilities - simultaneous control of material architecture and composition to promote cell viability and tissue engraftment while maintaining manufacturability and user-friendliness.

Thanks to our co-founder, Adam Jakus, Ph.D., who strategically developed this technology in response to existing limitations in the delivery and localization of hydrogel-based biomaterials. This work further expands upon an expansive patent portfolio at Dimension Inx beyond implantable materials to include injectables – all of which are dedicated to the design and manufacture of advanced #biomaterials for #tissuetherapeutic products that rebuild healthy tissues and restore organ function.

To learn more about our technology or if you're interested in joining a motivated team developing the next generation of regenerative therapeutics, please visit https://lnkd.in/d5ttjxk8.

We are excited to announce the recent issuance of two patents, U.S. Patent No. 11,896,740, which covers the manufacture of our highly tunable and porous Fluffy-X™ material family, and U.S. Patent No. 11,904,071, which covers the manufacture and use of our decellularized ECM-based Tissue Papers™ material family.
 
These material families highlight our platform’s unique capabilities - the control of both material structure and composition without compromising the ability to form complex constructs that demonstrate excellent handling properties and mechanical integrity. Our approach to the design and manufacture of advanced biomaterials for #tissuetherapeutic applications emphasizes the cellular and tissue microenvironment. We embrace the complex interplay between biology, material composition, microstructure, and macroarchitecture to direct optimal cell behavior and to create #regenerativemedicine products that rebuild healthy tissues and restore organ function.

Shout out to our co-founders, Ramille S., Ph.D. and Adam Jakus, Ph.D., who co-developed these technologies from nearly a decade of research at Northwestern University’s Tissue Engineering and Additive Manufacturing Lab. We are continuing to expand upon their foundation and advance our patent portfolio at Dimension Inx.

To learn more about our technology or if you're interested in joining an motivated team developing the next generation of tissue therapeutics, please visit https://lnkd.in/d5ttjxk8.

📣 Exciting News! Last week Dimension Inx was awarded Honorable Mention at the 2023 3D Printing Industry Awards in the category of Medical, Dental, or Health Application. We are grateful for this recognition celebrating our first product, CMFlex™, being used in patients. This achievement marks a notable advancement for 3D-printed medical applications, and we are honored to be included among all the outstanding nominees. A big thank you 🙏  to our team for their relentless effort that continues to drive our success. 🚀 

Also, a special congratulations to the category winner, Stratasys!

#3dprinting #additivemanufacturing #healthcareinnovation

https://lnkd.in/g9ZaEJdm

Thank you for sharing our story, Desktop Health! We're thrilled about our recent clinical launch of CMFlex™, the first 3D-printed regenerative bone graft product cleared by the FDA. 

We wouldn't be here without partners like you. Onwards and upwards.

#BiomedicalInnovation #Bioprinting #HealthcareInnovation #DesktopHealth #3DBioplotter #3DPrinting #MedicalInnovation

We are thrilled to announce the first patient use of CMFlex™, the FIRST FDA-cleared 3D-printed regenerative bone graft product. This huge milestone would not have been possible without the dedication and unwavering support of our exceptional team, visionary investors, and steadfast partners. We extend our heartfelt gratitude and admiration for their support and trust throughout this journey.

In these first-in-human surgeries, performed by distinguished surgeons Dr. Derek Steinbacher, Dr. Brian Farrell, and Dr. Robert Bosack, CMFlex has demonstrated its potential to positively impact patient lives.

This remarkable milestone underscores our commitment to advancing the field of regenerative medicine, with CMFlex paving the way for innovative solutions for patients. We are immensely proud of this achievement and look forward to a future filled with possibilities and groundbreaking discoveries.

#DimensionInx #CMFlex #RegenerativeMedicine #Innovation #Biotechnology #MedicalAdvancements

https://lnkd.in/g2bYAsXb

10 days until Alliance for Regenerative Medicine’s #CGMesa23! Our team looks forward to connecting with senior executives and top stakeholders Oct 10-12 to tackle the most pressing issues in cell and gene therapies. Send us a partnering request to explore how we use our 3D-printed biomaterials platform to develop #regenerative therapeutics that boost cell viability and engraftment. 
Learn more: https://lnkd.in/eiUpMy4

Metric
Company Name	Dimension Inx	Oxford Performance Materials, Inc.	Akkuratio
Symbol
MSH ID	COM:DIMENSIONINX	COM:OXFORDPM	DE:AKKURATIO
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Technology	Technology
Industry	Biotechnology	Manufacturing	Manufacturing
Country	US	US	DE
Stage
Employee Count	11
Website	dimensioninx.com	oxfordpm.com	akkuratio.de
LinkedIn	dimension-inx		akkuratio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	445
Web Traffic Growth	0.03
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DIME

COM:DIMENSIONINX

Dimension Inx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue